Analysts Expect Iovance Biotherapeutics Inc (IOVA) to Announce -$0.29 EPS

Equities analysts forecast that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will announce earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.37). Iovance Biotherapeutics posted earnings of ($0.26) per share in the same quarter last year, which would indicate a negative year over year growth rate of 11.5%. The business is scheduled to report its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.23) per share for the current year, with EPS estimates ranging from ($1.47) to ($0.72). For the next year, analysts expect that the business will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.69) to ($0.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Iovance Biotherapeutics.

Several brokerages recently weighed in on IOVA. Chardan Capital reissued a “buy” rating on shares of Iovance Biotherapeutics in a report on Wednesday, March 13th. Oppenheimer reissued a “buy” rating on shares of Iovance Biotherapeutics in a report on Tuesday, March 19th. Robert W. Baird began coverage on Iovance Biotherapeutics in a report on Wednesday, February 6th. They issued an “outperform” rating and a $29.00 price objective for the company. BidaskClub raised Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th. Finally, ValuEngine lowered Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.86.

IOVA traded up $0.03 during trading hours on Friday, hitting $9.51. The stock had a trading volume of 780,092 shares, compared to its average volume of 935,330. Iovance Biotherapeutics has a 1 year low of $7.26 and a 1 year high of $18.25. The firm has a market cap of $1.17 billion, a P/E ratio of -7.49 and a beta of 1.92.

Hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. boosted its stake in Iovance Biotherapeutics by 58.6% in the 4th quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 3,000 shares during the period. Kalos Management Inc. bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $93,000. Great West Life Assurance Co. Can boosted its position in shares of Iovance Biotherapeutics by 67.4% during the 4th quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 5,853 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at about $130,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Iovance Biotherapeutics by 66.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,374 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 6,162 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Further Reading: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.